Dipyridodiazepinone derivatives; synthesis and anti HIV-1 activity

• Nisachon Khunnawutmanotham,
• Nitirat Chimnoi,
• Arunee Thitithanyanont,
• Patchreenart Saparpakorn,
• Kiattawee Choowongkomon,
• Pornpan Pungpo,
• Supa Hannongbua and
• Supanna Techasakul

Beilstein J. Org. Chem. 2009, 5, No. 36, doi:10.3762/bjoc.5.36

• : AIDS; anti HIV-1 RT; dipyridodiazepinone; nevirapine; synthesis; Introduction Dipyridodiazepinone nevirapine (1) [1] (Figure 1) is a potent non-nucleoside inhibitor of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) and is approved as a therapeutic agent for the treatment of AIDS

• the help of Dr. Carrie Dykes of the University of Rochester, New York for the mutant clones, K103N and Y181C; and Dr. Hiroaki Mitsuya of the HIV and AIDS Malignancy Branch, USA for the WT clone.

Sordarin, an antifungal agent with a unique mode of action

• Huan Liang

Beilstein J. Org. Chem. 2008, 4, No. 31, doi:10.3762/bjoc.4.31

• immunosuppressed patients, especially those suffering from AIDS or cancer, fungal infections have become a significant, often life-threatening problem [1][2]. Present treatments rely on antifungals such as polyene antibiotics (amphotericin B), nucleoside analogs (5-fluorocytosine) and azoles (fluoconazole

Vinylogous Mukaiyama aldol reactions with 4-oxy-2-trimethylsilyloxypyrroles: relevance to castanospermine synthesis

• Roger Hunter,
• Sophie C. M. Rees-Jones and
• Hong Su

Beilstein J. Org. Chem. 2007, 3, No. 38, doi:10.1186/1860-5397-3-38

• (Figure 2). The latter is an indolizidine alkaloid that has received significant attention from the synthetic organic community in view of its potent biological activity as an α- and β-glycosidase inhibitor with promising anti-diabetic,[19] anti-cancer,[20] anti-viral [21] and anti-AIDS activity.[22] The

Synthesis and glycosidase inhibitory activity of new hexa- substituted C8-glycomimetics

• Olivia Andriuzzi,
• Christine Gravier-Pelletier,
• Gildas Bertho,
• Thierry Prangé and
• Yves Le Merrer

Beilstein J. Org. Chem. 2005, 1, No. 12, doi:10.1186/1860-5397-1-12

• as diabetes, cancer and viral infections including AIDS. Thus, inhibition of intestinal α-glucosidases can be used to treat diabetes through the lowering of blood glucose levels, and α-glucosidase inhibitors are being marketed against type 2 (non-insulinodependent mellitus) diabetes (i.e.: Glyset® or